GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abeona Therapeutics Inc (FRA:PCJ) » Definitions » Shiller PE Ratio

Abeona Therapeutics (FRA:PCJ) Shiller PE Ratio : (As of May. 26, 2024)


View and export this data going back to 1980. Start your Free Trial

What is Abeona Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Abeona Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Abeona Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abeona Therapeutics Shiller PE Ratio Chart

Abeona Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Abeona Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Abeona Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Abeona Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abeona Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abeona Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Abeona Therapeutics's Shiller PE Ratio falls into.



Abeona Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Abeona Therapeutics's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Abeona Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-1.067/131.7762*131.7762
=-1.067

Current CPI (Mar. 2024) = 131.7762.

Abeona Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -464.784 100.560 -609.067
201409 -80.510 100.428 -105.641
201412 -12.826 99.070 -17.060
201503 -2.310 99.621 -3.056
201506 -3.564 100.684 -4.665
201509 -4.232 100.392 -5.555
201512 -1.377 99.792 -1.818
201603 -3.817 100.470 -5.006
201606 -4.450 101.688 -5.767
201609 -1.782 101.861 -2.305
201612 -4.503 101.863 -5.825
201703 -3.039 102.862 -3.893
201706 -4.673 103.349 -5.958
201709 -2.727 104.136 -3.451
201712 -4.014 104.011 -5.086
201803 -4.460 105.290 -5.582
201806 -5.564 106.317 -6.896
201809 -7.285 106.507 -9.013
201812 -7.911 105.998 -9.835
201903 -8.629 107.251 -10.602
201906 -10.841 108.070 -13.219
201909 -7.945 108.329 -9.665
201912 -6.525 108.420 -7.931
202003 -11.765 108.902 -14.236
202006 -3.108 108.767 -3.765
202009 -1.698 109.815 -2.038
202012 -3.493 109.897 -4.188
202103 -3.570 111.754 -4.210
202106 -3.262 114.631 -3.750
202109 -1.530 115.734 -1.742
202112 -9.956 117.630 -11.153
202203 -3.450 121.301 -3.748
202206 -1.287 125.017 -1.357
202209 -1.010 125.227 -1.063
202212 -0.379 125.222 -0.399
202303 -0.504 127.348 -0.522
202306 -0.849 128.729 -0.869
202309 -0.450 129.860 -0.457
202312 -0.587 129.419 -0.598
202403 -1.067 131.776 -1.067

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Abeona Therapeutics  (FRA:PCJ) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Abeona Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Abeona Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Abeona Therapeutics (FRA:PCJ) Business Description

Traded in Other Exchanges
Address
1330 Avenue of the Americas, 33rd Floor, New York, NY, USA, 10019
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its lead clinical programs consist of EB-101, autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, adeno-associated virus-based gene therapy for Sanfilippo syndrome type A, and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B.

Abeona Therapeutics (FRA:PCJ) Headlines

No Headlines